<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:07:00Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5828106" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5828106</identifier><datestamp>2018-07-08</datestamp><setSpec>wtpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9216904</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">2419</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id>
      <journal-title-group>
        <journal-title>Nature genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1061-4036</issn>
      <issn pub-type="epub">1546-1718</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5828106</article-id>
      <article-id pub-id-type="pmcid">PMC5828106</article-id>
      <article-id pub-id-type="pmc-uid">5828106</article-id>
      <article-id pub-id-type="pmid">29311636</article-id>
      <article-id pub-id-type="pmid">29311636</article-id>
      <article-id pub-id-type="doi">10.1038/s41588-017-0022-7</article-id>
      <article-id pub-id-type="manuscript">ems75137</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Loss-of-function variants in <italic>ADCY3</italic> increase risk of
obesity and type 2 diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Grarup</surname>
            <given-names>Niels</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Moltke</surname>
            <given-names>Ida</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andersen</surname>
            <given-names>Mette K.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dalby</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vitting-Seerup</surname>
            <given-names>Kristoffer</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kern</surname>
            <given-names>Timo</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahendran</surname>
            <given-names>Yuvaraj</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JÃ¸rsboe</surname>
            <given-names>Emil</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Larsen</surname>
            <given-names>Christina V. L.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dahl-Petersen</surname>
            <given-names>Inger K.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gilly</surname>
            <given-names>Arthur</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suveges</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dedoussis</surname>
            <given-names>George</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zeggini</surname>
            <given-names>Eleftheria</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pedersen</surname>
            <given-names>Oluf</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andersson</surname>
            <given-names>Robin</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bjerregaard</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JÃ¸rgensen</surname>
            <given-names>Marit E.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Albrechtsen</surname>
            <given-names>Anders</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hansen</surname>
            <given-names>Torben</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
<label>1</label>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty
of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</aff>
      <aff id="A2">
<label>2</label>The Bioinformatics Centre, Department of Biology, University of
Copenhagen, Copenhagen, Denmark</aff>
      <aff id="A3">
<label>3</label>Biotech Research &amp; Innovation Centre (BRIC), University of
Copenhagen, Copenhagen, Denmark</aff>
      <aff id="A4">
<label>4</label>National Institute of Public Health, University of Southern Denmark,
Copenhagen, Denmark</aff>
      <aff id="A5">
<label>5</label>Greenland Centre for Health Research, University of Greenland, Nuuk,
Greenland</aff>
      <aff id="A6">
<label>6</label>Department of Human Genetics, Wellcome Trust Sanger Institute,
Hinxton, UK</aff>
      <aff id="A7">
<label>7</label>Department of Nutrition and Dietetics, Harokopio University of
Athens, Athens, Greece</aff>
      <aff id="A8">
<label>8</label>Steno Diabetes Center Copenhagen, Gentofte, Denmark</aff>
      <aff id="A9">
<label>9</label>Faculty of Health Sciences, University of Southern Denmark, Odense,
Denmark</aff>
      <author-notes>
        <corresp id="CR1">Corresponding authors: Torben Hansen,
<email>torben.hansen@sund.ku.dk</email>, Anders Albrechtsen,
<email>albrecht@binf.ku.dk</email>, Marit E. JÃ¸rgensen,
<email>marit.eika.joergensen@regionh.dk</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>26</day>
        <month>1</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>08</day>
        <month>1</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>08</day>
        <month>7</month>
        <year>2018</year>
      </pub-date>
      <volume>50</volume>
      <issue>2</issue>
      <fpage>172</fpage>
      <lpage>174</lpage>
      <!--elocation-id from pubmed: 10.1038/s41588-017-0022-7-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">We have identified a variant in adenylate cyclase 3
(<italic>ADCY3</italic>) associated with markedly increased risk of obesity
and type 2 diabetes in the Greenlandic population. The variant disrupts a
splice-acceptor site and carriers display decreased <italic>ADCY3</italic> RNA
expression. Additionally, we observe an enrichment of rare
<italic>ADCY3</italic> loss-of-function variants among type 2 diabetes
patients in trans-ethnic cohorts. These findings provide novel information on
disease etiology relevant for future treatment strategies.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">Identification of homozygous loss-of-function mutations in humans may readily
inform about the biological impact of specific genes and point to novel drug targets. We
previously identified a loss-of-function variant in <italic>TBC1D4</italic> segregating
at high frequency in the Greenlandic population displaying a high impact on risk of type
2 diabetes<xref rid="R1" ref-type="bibr">1</xref>, confirming the advantage of studying
the Greenlandic population due to its extreme demographic history<xref rid="R2" ref-type="bibr">2</xref>. Motivated by this, we screened for novel loss-of-function
variants in the exome sequencing data from 27 individuals in nine trios that were used
to identify the causal <italic>TBC1D4</italic> loss-of-function variant<xref rid="R1" ref-type="bibr">1</xref>. We identified 46 such variants (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table 1</xref>) and
intersected the location of these variants with loci known to associate with obesity or
body mass index (BMI) (<xref ref-type="supplementary-material" rid="SD2">Supplementary
Fig. 1</xref>). One of the variants, which was present in one copy in one of the
trio's parents, was situated in a locus where a common non-coding variant has
been shown to be associated with BMI in adults and children in genome-wide association
studies (GWAS)<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>. The variant (hg19: 2-25050478-C-T, c.2433-1G&gt;A) is predicted to
destroy a splice-acceptor site in exon 14 (NM_004036.4) (<xref ref-type="fig" rid="F1">Fig. 1A</xref>) of <italic>ADCY3</italic>. For this reason, we investigated the
specific variant further by genotyping it in two Greenlandic cohorts. This revealed an
overall minor allele frequency of 2.3% in the Greenlandic study population
(<italic>N</italic>=4,038, <italic>N</italic>-heterozygous=172,
<italic>N</italic>-homozygous=7), and a frequency of 3.1% in the Inuit ancestry part of
the population. Importantly, the seven homozygous carriers had a 7.3 kg/m<sup>2</sup>
higher BMI (<italic>P</italic>=0.00094) compared with the remaining study population
(<xref ref-type="table" rid="T1">Table 1</xref>). Interestingly, we also observed
that three of the seven homozygous carriers had type 2 diabetes
(<italic>P</italic>=7.8Ã10<sup>-5</sup>, <xref ref-type="table" rid="T1">Table 1</xref>), while one had impaired fasting glucose and one impaired glucose
tolerance. Notably, the association with type 2 diabetes remained significant after
adjustment for BMI (<italic>P</italic>=6.5Ã10<sup>-4</sup>), suggesting it is not
simply mediated by increased BMI. The effects on BMI and type 2 diabetes were also
observed, although with smaller effect sizes, when data were analyzed according to an
additive genetic model (<xref ref-type="table" rid="T1">Table 1</xref>). However, when
we compared the recessive and additive models with the full genotype model, we rejected
the additive model (BMI: <italic>P</italic>=0.002; type 2 diabetes:
<italic>P</italic>=0.004), but not the recessive model (BMI: <italic>P</italic>=0.17;
type 2 diabetes: <italic>P</italic>=0.095). This suggests that the recessive model is
appropriate for explaining the effect of the c.2433-1G&gt;A variant.</p>
    <p id="P3">To further characterize homozygous <italic>ADCY3</italic> c.2433-1G&gt;A
carriers in the Greenlandic cohorts, we analyzed a number of additional traits related
to BMI and type 2 diabetes. The homozygous carriers had an 8.1 percentage points higher
body fat percentage (<italic>P</italic>=0.0024) and a 17 cm larger waist circumference
(<italic>P</italic>=0.0017). In addition, the homozygous carriers had nominally
higher levels of fasting and 2-h plasma glucose after an oral glucose tolerance test
(<italic>P</italic>=0.022 and <italic>P</italic>=0.035, respectively; <xref ref-type="table" rid="T1">Table 1</xref>). Finally, we also observed nominally
significant effects on dyslipidemia and insulin resistance (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table 2</xref>).</p>
    <p id="P4">The c.2433-1G&gt;A <italic>ADCY3</italic> variant was not observed in
sequencing data of up to 138,000 individuals from non-Greenlandic populations collected
by the Genome Aggregation Database Consortium<xref rid="R5" ref-type="bibr">5</xref>
(gnomAD). To generalize our findings to other populations, we therefore investigated the
effect of loss-of-function variants in <italic>ADCY3</italic> more generally by
analyzing 18,176 samples with exome sequence data generated by the GoT2D, T2DGenes,
SIGMA and LuCAMP consortia<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>, which are available at
the Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D). No
homozygous <italic>ADCY3</italic> loss-of-function carriers were observed in this
dataset, but the analysis included seven predicted <italic>ADCY3</italic>
loss-of-function variants (<xref ref-type="fig" rid="F1">Fig. 1A</xref>) observed in the
heterozygous form in eight individuals, and we observed an enrichment of carriers among
type 2 diabetes cases compared with non-diabetic controls (7/8,845 in cases, 1/9,323 in
controls, OR 8.6, <italic>P=</italic>0.044, <xref ref-type="supplementary-material" rid="SD4">Supplementary Table 3-5</xref>). To further substantiate these findings,
exome sequence data from 9,928 Finnish individuals from the METSIM cohort<xref rid="R9" ref-type="bibr">9</xref> were screened for loss-of-function variants in
<italic>ADCY3</italic>; however, none were identified (Markku Laakso, personal
communication). Furthermore, we did not find any loss-of-function <italic>ADCY3</italic>
variants in whole genome sequence data for 3,124 individuals from two Greek isolated
populations as part of the HELIC study<xref rid="R10" ref-type="bibr">10</xref>.
Finally, in up to 138,000 individuals in the gnomAD data, 48 predicted loss-of-function
variants were found. All variants had minor allele frequency below 0.007% and only a
single homozygous loss-of-function carrier was found for the African-specific
<italic>ADCY3</italic> c.1072-1G&gt;A variant. Since we cannot obtain phenotypic
data for the gnomAD samples, we are unable to evaluate the impact of these variants on
obesity and type 2 diabetes.</p>
    <p id="P5">To investigate the functional impact of the <italic>ADCY3</italic>
c.2433-1G&gt;A variant, we performed deep RNA sequencing in leukocytes from 17
Greenlandic individuals (7 GG carriers, 6 GA carriers and 4 AA carriers). The RNA
sequencing data confirmed that <italic>ADCY3</italic> was expressed in the wild type GG
carriers and that exon 14 (NM_004036.4) of <italic>ADCY3</italic> was expressed and
spliced in its canonical form (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 2A</xref>). The inclusion of exon 14 in the mature mRNA was
further confirmed by RNA sequence data from adipose tissue of a healthy Caucasian female
donor<xref rid="R11" ref-type="bibr">11</xref>. Importantly, we found that the
overall RNA expression level of <italic>ADCY3</italic> was severely decreased in the
homozygous AA carriers, while the heterozygous GA carriers showed an intermediate
expression level (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The RNA sequencing data
further confirmed that the predicted disruption of exon 14 splice-acceptor site by
variant c.2433-1G&gt;A has an impact on the molecular phenotype. Specifically, the
data predict that two novel ADCY3 isoforms are expressed in the variant carriers: one
transcript isoform where exon 14 is skipped and an alternative splice-acceptor site at
exon 15 is used and one transcript isoform in which the intron between exon 13 and exon
14 is retained (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig.
2B</xref>). We quantified these alternative splicing events by comparing the
expression of the three predicted ADCY3 isoforms using isoform fraction (IF) (<xref ref-type="fig" rid="F1">Fig. 1C</xref>) and the percentage of spliced in (PSI) at
the relevant splice sites (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 2B</xref>)<italic>.</italic> Both analyses demonstrated that the
homozygous AA carriers had severely affected splice pattern and mainly used intron
retention (median IF 0.38, median PSI 75%) or exon skipping (IF 0.53, PSI 24%),
while the wild type GG carriers had the canonical splice pattern (IF 0.88, PSI
87%). In all analyses, heterozygous carriers showed an intermediate level of alternative
splicing (<xref ref-type="fig" rid="F1">Fig. 1C</xref>; <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 2B &amp;
C</xref>). Importantly, we predict the isoform with an intron retention to be sensitive
to nonsense mediated decay due to a premature stop codon<xref rid="R12" ref-type="bibr">12</xref> (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). This predicted
degradation naturally would lead to further reduction of ADCY3 protein levels.</p>
    <p id="P6"><italic>ADCY3</italic> encodes an adenylate cyclase with a wide tissue
distribution showing high levels in subcutaneous and visceral adipose tissue,
intermediate levels in brain and rather low levels in pancreas and skeletal muscle in
GTEx Project data. ADCY3 catalyzes the synthesis of cAMP from ATP. cAMP is an essential
second-messenger in intracellular signaling downstream of key metabolic mediators such
glucagon-like peptide 1, ghrelin and Î±-melanocyte stimulating hormone<xref rid="R13" ref-type="bibr">13</xref>, and cAMP signaling has been linked to control
of adipose tissue development and function, as well as insulin secretion in beta
cells<xref rid="R14" ref-type="bibr">14</xref>. In addition, mouse models have
indicated that ADCY3 plays an important role in the regulation of adiposity and glucose
homeostasis. Hence, in mice, <italic>Adcy3</italic> haplo-insufficiency causes impaired
insulin sensitivity and dyslipidaemia<xref rid="R15" ref-type="bibr">15</xref>,
<italic>Adcy3</italic> gain-of-function protects from diet induced obesity<xref rid="R16" ref-type="bibr">16</xref>, and <italic>Adcy3</italic> knock-out mice show
increased fat mass, hyperphagia, depression-like phenotypes, and leptin resistance<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>.
Possibly, leptin resistance occurs through disrupted cAMP signaling in primary cilia in
hypothalamus affecting downstream signaling and morphology of the neurons<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>.
Interestingly, previously described syndromic forms of obesity, including Bardet-Biedl
and AlstrÃ¶m syndrome, are caused by altered function of primary cilia, and are
besides from obesity characterized by diabetes<xref rid="R19" ref-type="bibr">19</xref>.
Furthermore, common variation in <italic>ADCY5,</italic> a gene in the same family as
<italic>ADCY3</italic>, is known to be associated with fasting plasma glucose levels
and risk of type 2 diabetes<xref rid="R20" ref-type="bibr">20</xref>.</p>
    <p id="P7">In humans, common variants in the <italic>ADCY3</italic> locus have been
associated with higher BMI<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref> and total as well as truncal fat mass<xref rid="R21" ref-type="bibr">21</xref>. Thus, the phenotype observed in Greenlandic homozygous
loss-of-function carriers, characterized by truncal adiposity, insulin resistance,
dyslipidemia and type 2 diabetes, is in accordance with and elaborates on the phenotype
observed for GWAS-identified variants. Our findings for loss-of-function carriers
implicate <italic>ADCY3</italic> as the causal transcript in the reported
GWAS-identified locus, and coherent evidence from genetic and biological studies suggest
that pharmacological modulation of this target may possibly be a valid future therapy
for obesity and type 2 diabetes.</p>
    <p id="P8">In conclusion, we identified an <italic>ADCY3</italic> loss-of-function variant
in Greenlandic Inuit, which increases adiposity and risk of type 2 diabetes in
homozygous carriers, and to a lesser extent in heterozygous carriers. Concomitantly, we
detected decreased <italic>ADCY3</italic> RNA expression levels in homozygous carriers,
and again to a lesser extent in heterozygous carriers. Furthermore, we show that the
variant disrupts a splice-acceptor site, triggering exon skipping or intron retention,
where the latter is predicted to confer nonsense-mediated decay. The association with
type 2 diabetes was substantiated in trans-ethnic heterozygous carriers of rare
<italic>ADCY3</italic> variants underlining the possible role of ADCY3 as a future
target for prevention and treatment of obesity and type 2 diabetes.</p>
    <sec sec-type="methods" id="S1" specific-use="web-only">
      <title>Online methods</title>
      <sec id="S2">
        <title>Study samples</title>
        <p id="P9">The Greenlandic samples are from two different cohorts: B99
(<italic>N</italic>=1,401) and Inuit Health in Transition (IHIT)
(<italic>N</italic>=3,115), which were collected in Greenland as a part of
general population health surveys conducted in 1999-2001 and 2005-2010,
respectively<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>. Two hundred and ninety-five individuals overlapped
between the two cohorts and were assigned to the B99 dataset. Clinical
characteristics of the participants are shown in <xref ref-type="supplementary-material" rid="SD4">Supplementary Table
6</xref>.</p>
      </sec>
      <sec id="S3">
        <title>Ethical considerations</title>
        <p id="P10">The study has received ethics approval from the Commission for
Scientific Research in Greenland (project 2011-13, ref. no. 2011-056978; and
project 2013-13, ref.no. 2013-090702) and was conducted in accordance with the
ethical standards of the Declaration of Helsinki, second revision. All
participants gave written consent after being informed about the study both
orally and in writing.</p>
      </sec>
      <sec id="S4">
        <title>Phenotypic data</title>
        <p id="P11">Height and weight were measured wearing light indoor clothes. Waist
circumference was measured midway between the rib cage and the iliac crest and
hip circumference at its maximum. Weight was measured on a standard electronic
clinical scale. Fat percentage was calculated from bioimpedance measurements
(Tanita TBF-300MA) in IHIT participants. Intraabdominal adipose tissue was
assessed by ultrasonography, which is considered a valid and reproducible method
compared with CT and MRI<xref rid="R24" ref-type="bibr">24</xref>, using a 3.5
MHz transducer with the participant in supine position and at the end of a
normal expiration. Tests for intra- and inter-observer variation were performed
in IHIT and were in the range of 1.9-5.6% <xref rid="R25" ref-type="bibr">25</xref>. In IHIT, all participants underwent an oral glucose tolerance
test (OGTT). In B99, participants above 24 years of age had fasting blood
samples taken and participants above 35 years underwent an OGTT. At the baseline
health examination, venous blood samples were drawn after an overnight fast of
at least 8 hours. After this, participants received a standard 75-g OGTT, with
blood samples drawn 2 hours after the glucose intake. Only fasting venous plasma
glucose was measured in participants with known diabetes. Fasting and 2-hours
(2-h) plasma glucose values were analyzed with the Hitachi 912 system (Roche
Diagnostics, Mannheim, Germany). Fasting and 2-h serum insulin levels were
analyzed by an immunoassay method excluding des-31,32 split products and intact
proinsulin (AutoDELFIA; Perkin Elmer, Waltham, MA). Indices of insulin
sensitivity and insulin secretion were derived from plasma glucose and serum
insulin measures from the OGTT. Hepatic insulin sensitivity was estimated by the
homeostasis model assessment (HOMA-IR = fasting glucose [mmol/L] Ã
(fasting insulin [pmol/L]/6.945) / 22.5) <xref rid="R26" ref-type="bibr">26</xref> and by a peripheral insulin sensitivity index
(ISI<sub>0,120</sub>) calculated as: ISI<sub>0,120</sub> = ( ((75000 +
(fasting glucose[mmol/L] Ã 18 â 2-h glucose Ã 18) Ã
0.19 Ã weight [kg])/120) / ((fasting glucose[mmol/L] Ã 18 + 2-h
glucose[mmol/L] Ã 18) / 2) ) / log((fasting insulin[pmol/L]/6.945 + 2-h
insulin[pmol/L]/6.945)/2) <xref rid="R27" ref-type="bibr">27</xref>. Analyses of
quantitative glycemic traits were performed excluding individuals with
previously diagnosed diabetes. Individuals taking lipid-lowering medication were
removed in analysis of fasting serum lipids. Dichotomous glycaemia variables
were constructed to test for association with type 2 diabetes classified
according to the World Health Organization criteria<xref rid="R28" ref-type="bibr">28</xref>.</p>
      </sec>
      <sec id="S5">
        <title>Identification and selection of loss-of function variants to study</title>
        <p id="P12">To identify the novel loss-of-function variants in the Greenlandic
population we used the exome data from 27 Greenlandic individuals in nine trios
presented previously<xref rid="R1" ref-type="bibr">1</xref>. In this dataset, we
identified 46 loss-of-function variants, which were not present in dbSNP
(version 138 and below) and that were not present in NHLBI Exome Sequencing
Project (ESP) (<xref ref-type="supplementary-material" rid="SD3">Supplementary
Table 1</xref>). We then used the GWAS catalogue (downloaded January 2013)
to assign known associations to the loci with the loss-of-function variants
using associations with <italic>P</italic>-values of less than 10<sup>-7</sup>.
Finally, we selected the variants with known associations to obesity or BMI for
further study. This selection procedure left us with one predicted
loss-of-function variant, <italic>ADCY3</italic> c.2433-1G&gt;A (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 1</xref>).
This variant is located in <italic>ADCY3</italic> and was present in a single
parent in one of the nine trios in heterozygous form.</p>
      </sec>
      <sec id="S6">
        <title>Genotype data</title>
        <p id="P13">Subsequently, we genotyped <italic>ADCY3</italic> c.2433-1G&gt;A in
the two Greenlandic cohorts, IHIT and B99, using KASP Genotyping Assay (LGC
Genomics, Hoddlesdon, UK). Genotyping call rate was 99.2% and no mismatches were
observed in 362 samples genotyped in duplicate. For the association testing, we
used quality filtered MetaboChip genotype data to base our genetic similarity
matrix estimates on. The genotyping and quality filtering of the MetaboChip data
has been described in detail earlier<xref rid="R29" ref-type="bibr">29</xref>.
The filtered MetaboChip dataset contains data from 2,791 individuals from IHIT
and 1,336 individuals from B99 and we have <italic>ADCY3</italic>
c.2433-1G&gt;A genotyping data for 4,038 of these individuals, 2,779 from
IHIT and 1,259 from B99.</p>
      </sec>
      <sec id="S7">
        <title>Association testing and replication</title>
        <sec id="S8">
          <title>Greenlandic cohorts</title>
          <p id="P14">To test for association between the <italic>ADCY3</italic> variant
and the different phenotypes of interest we used a linear mixed model,
implemented in the software GEMMA<xref rid="R30" ref-type="bibr">30</xref>,
in order to account for relatedness and admixture<xref rid="R1" ref-type="bibr">1</xref>. For each phenotype, GEMMA was applied to data from
the subset of individuals across the two cohorts with information available
about that specific phenotype. The genetic similarity matrix required as
input to GEMMA was estimated from MetaboChip genotype data<xref rid="R1" ref-type="bibr">1</xref>. For each phenotype, we performed two
association tests: a test where we assumed a recessive effect model and a
test where we assumed an additive effect model. All tests were performed
with sex, age and cohort included as covariates. An additional analysis also
included BMI as covariate. Before all tests for association with
quantitative traits, we quantile transformed the phenotype data to a normal
distribution separately for each sex, which resulted in the results reported
as <italic>Î²</italic><sub>SD</sub>, se<sub>SD</sub> and
<italic>P</italic>. However, to get effect sizes in the units the traits
were measured in, we also performed the analyses without transforming the
phenotype data, which resulted in the results reported as
<italic>Î²</italic>. For the binary trait, type 2 diabetes, we did
not perform any transformation and the test results are reported as
<italic>Î²</italic> and <italic>P</italic>.</p>
          <p id="P15">To assess the appropriateness of the recessive effect model and the
additive effect model for BMI and type 2 diabetes we compared each of these
effects models against a full genotype model, where each of the three
genotypes have an independent effect. To do this, we used the same linear
model framework as we did for the association tests. These additional tests
were only performed in the IHIT cohort because there were no homozygous
carriers in B99, which in practice means the tests cannot be performed if
B99 is included.</p>
        </sec>
        <sec id="S9">
          <title>Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal
(AMP-T2D)</title>
          <p id="P16">Data from AMP-T2D generated as part of the GoT2D, T2DGenes, SIGMA
and LuCAMP consortia<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref> were queried for association between a burden of
loss-of-function variants in <italic>ADCY3</italic> and type 2 diabetes. The
data contained 18,869 samples with exome sequence data of which 18,176
samples were informative for type 2 diabetes. Samples originated from five
ancestries (6,356 Europeans, 5,722 Hispanic, 2,199 South Asians, 2,158 East
Asians and 1,741 African Americans). Variants annotated as stop-gained,
frameshift or in a splice adapter/donor site were considered
loss-of-function. Burden association analyses were performed with each
individual coded as carrying a loss-of-function variant or not. We used
logistic regression and adjusted for principal components 1-4 as well as age
and sex by including these as covariates. We also analyzed all other genes
with at least five loss-of-function variants with at least one mutation
carrier for each variant. Only loss-of-function variants with a minor allele
frequency (MAF) &lt;5% were used. This analysis showed that there is no
general inflation in the test statistic (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig.
3</xref>).</p>
        </sec>
        <sec id="S10">
          <title>Greek isolated populations</title>
          <p id="P17">As part of the HELIC study<xref rid="R10" ref-type="bibr">10</xref>,
1,642 samples from the Pomak villages in Northern Greece and 1,482 samples
from the Mylopotamos villages in Crete were sequenced at an average depth of
18.6x and 22.5x, respectively using the HiSeqX platform. Adapter-ligated
libraries were amplified by 6 cycles of PCR and subjected to DNA sequencing
according to manufacturerâs instructions. GVCFs were created for 200
equally sized chunks using GATK HaplotypeCaller v3.5, combined into batches
of 150 samples using GATK CombineGVCFs and called using GATK GenotypeGVCFs.
Variant-level QC was performed using GATK VQSR v.3.5.</p>
        </sec>
      </sec>
      <sec id="S11">
        <title>Estimation of admixture proportions, ancestral allele frequencies and
relatedness</title>
        <p id="P18">For the Greenlanders, all admixture proportions were obtained from ref.
<xref rid="R1" ref-type="bibr">1</xref>. To estimate the ancestral Inuit
allele frequencies for the <italic>ADCY3</italic> variant we performed maximum
likelihood estimation using the likelihood model from ADMIXTURE<xref rid="R31" ref-type="bibr">31</xref> with the admixture proportions fixed and
including only genotype data from the variant of interest. To achieve the
maximum likelihood estimates we applied an EM-algorithm. We estimated
relatedness using relateAdmix<xref rid="R32" ref-type="bibr">32</xref> based on
the estimated admixture proportions. None of the seven homozygous carriers are
closely related (2<sup>nd</sup>-degree or closer), however one pair may be first
cousins with an estimated kinship coefficient of 0.08.</p>
      </sec>
      <sec id="S12">
        <title>RNA sequencing analysis</title>
        <p id="P19">RNA sequencing was performed on leukocytes from 17 Greenlandic
individuals (7 GG carriers, 6 GA carriers and 4 AA carriers). The total RNA was
extracted from 2.5 mL of peripheral blood with the PAXGene Blood miRNA Kit
(Qiagen) according to the manufacturer's protocol, and subjected to
on-column DNase I treatment with RNase-free Dnase (Qiagen). The RNA quality and
purity were checked using Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit)
and NanoDropâ¢, respectively.</p>
        <p id="P20">The RNA sequencing library was prepared following the instructions of
the TruSeq RNA Sample Prep Kit v2 (Illumina): For mRNA isolation and
fragmentation 200 ng of total RNA was purified by oligo-dT beads before
fragmentation with Elute, Prime, Fragment Mix. First-strand cDNA was generated
using First Strand Mix and SuperScript II (Invitrogen) reverse transcription
master mix (reaction condition: 25Â°C for 10 min; 42Â°C for 50 min;
70Â°C for 15 min). The second-strand was synthesized by adding Second
Strand Master Mix (16Â°C for 1h). The fragmented cDNA was end-repaired and
purified with Ampure XP Beads (AGENCOURT). A-Tailing Mix was added and incubated
(37Â°C for 30 min). For the adapter ligation, Adenylate 3'Ends DNA,
RNA Index Adapter and Ligation Mix, were mixed and incubated (30Â°C for 10
min). End-repaired DNA was purified with Ampure XP Beads (AGENCOURT). Several
rounds of PCR amplification with PCR Primer Cocktail and PCR Master Mix were
performed to enrich the cDNA fragments. The PCR products were purified with
Ampure XP Beads (AGENCOURT). The average molecule length was measured using the
Agilent 2100 bioanalyzer instrument (Agilent DNA 1000 Reagents), and by
real-time quantitative PCR (TaqMan Probe). The qualified libraries were
amplified on cBot to generate the cluster on the flowcell (TruSeq PE Cluster Kit
V3âcBotâHS, Illumina). The amplified flow cell was sequenced
paired-end on the HiSeq 4000 System (TruSeq SBS KIT-HS V3, Illumina).</p>
        <p id="P21">The obtained RNA-seq libraries, as well as one RNA-seq library from
adipose tissue of a healthy Caucasian female<xref rid="R11" ref-type="bibr">11</xref> were processed by Trimmomatic v 0.32 <xref rid="R33" ref-type="bibr">33</xref> trimming the reads using HEADCROP:11 LEADING:22
SLIDINGWINDOW:4:22 MINLEN:25. Quality of all libraries were checked with FastQC,
before and after trimming. Trimmed reads were mapped un-stranded to the human
reference genome (hg19) using Hisat2 v2.0.1-beta<xref rid="R34" ref-type="bibr">34</xref> with splice site information from GENCODE v19 <xref rid="R35" ref-type="bibr">35</xref> and set to annotate properly paired
reads as those with a minimum insert size from 0 to 1000 nucleotides. Sashimi
plots<xref rid="R36" ref-type="bibr">36</xref> were generated from the IGV
genome browser<xref rid="R37" ref-type="bibr">37</xref>. PSI was calculated as
r<sub>exon:intron</sub> / (r<sub>exon:intron</sub> + r<sub>exon:exon</sub>)
where r is the number of reads indicating the different splice patterns.
r<sub>exon:intron</sub> was obtained by extracting relevant GENCODE v19
<xref rid="R35" ref-type="bibr">35</xref> exon:intron boundaries +/- 3
nucleotides. Reads mapping to these regions were quantified using featureCounts
from the R package Rsubread<xref rid="R38" ref-type="bibr">38</xref> specifying
countChimericFragments=FALSE and minOverlap=6, ensuring that reads map across
the exon boundary. r<sub>exon:exon</sub> was calculated by running featureCounts
with the juncCounts=TRUE parameter. Plots were made using ggplot2. For
transcript quantification, we constructed a gtf file containing three versions
of GENCODE v19 transcript ENST00000260600.5, the longest transcript for ADCY3.
The corresponding genomic sequences were extracted using Cufflinks gffread
tool<xref rid="R39" ref-type="bibr">39</xref> and a Salmon index was build
using Salmon v0.8.2 <xref rid="R40" ref-type="bibr">40</xref>. Untrimmed fastq
files were used to quantify the resulting transcripts using Salmon v0.8.2
<sup>0</sup>. Calculations of isoform fractions and prediction of functional
consequences, were done with the R package IsoformSwitchAnalyzeR<xref rid="R12" ref-type="bibr">12</xref> using standard parameters except the
filtering where geneExpressionCutoff = 1, and isoformExpressionCutoff = 0.5, and
keepIsoformInAllConditions=TRUE, supplied to the preFilter() function. Hmmer
scan v.3.1 <xref rid="R41" ref-type="bibr">41</xref> was used to predict pfamA
protein domains as described in the IsoformSwitchAnalyzeR vignette and
integrated into the analysis by the analyzePFAM() function. The functional
consequences of isoform switches was predicted by IsoformSwitchAnalyzeRâs
analyzeSwitchConsequences() function.</p>
      </sec>
      <sec id="S13">
        <title>Data availability</title>
        <p id="P22">The Greenlandic exome sequencing and RNA sequencing data have been
deposited at the European Genome-phenome Archive (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/home">https://www.ebi.ac.uk/ega/home</ext-link>) under accession number
EGAS00001002727. Trans-ethnic data analyzed in the project are available at
<ext-link ext-link-type="uri" xlink:href="http://www.type2diabetesgenetics.org/gene/geneInfo/ADCY3">http://www.type2diabetesgenetics.org/gene/geneInfo/ADCY3</ext-link> upon
registration at the website. Repositories of genetic variation and gene
expression were queried at <ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">http://gnomad.broadinstitute.org/</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.gtexportal.org/">https://www.gtexportal.org/</ext-link>, respectively.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>Reporting summary</label>
        <media xlink:href="NIHMS75137-supplement-Reporting_summary.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" xlink:type="simple" id="d36e882" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD2">
        <label>Supplementary figures</label>
        <media xlink:href="NIHMS75137-supplement-Supplementary_figures.doc" mimetype="application" mime-subtype="msword" orientation="portrait" xlink:type="simple" id="d36e886" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD3">
        <label>Supplementary table 1</label>
        <media xlink:href="NIHMS75137-supplement-Supplementary_table_1.xlsx" mimetype="application" mime-subtype="octet-stream" orientation="portrait" xlink:type="simple" id="d36e890" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD4">
        <label>Supplementary tables 2-5 </label>
        <media xlink:href="NIHMS75137-supplement-Supplementary_tables_2-5_.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" xlink:type="simple" id="d36e894" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S14">
      <title>Acknowledgements</title>
      <p>We gratefully acknowledge the participants in the Greenlandic health surveys. We
thank Dr. Flannick, Broad Institute, US for help with obtaining the AMP-T2D exome
sequencing data. The Novo Nordisk Foundation Center for Basic Metabolic Research is
an independent Research Center at the University of Copenhagen partially funded by
an unrestricted donation from the Novo Nordisk Foundation (<ext-link ext-link-type="uri" xlink:href="http://www.metabol.ku.dk/">www.metabol.ku.dk</ext-link>). This project was also funded by the Danish
Council for Independent Research (Sapere Aude DFF-Ung Eliteforsker grant 11-120909
from FSS to I.M.; DFF-4090-00244 from FNU to I.M.; Sapere Aude DFF-Forskningsleder
6108-00038B from FNU to R.A., DFF-4181-00383 to A.A.), the Steno Diabetes Center
Copenhagen (<ext-link ext-link-type="uri" xlink:href="www.steno.dk">www.steno.dk</ext-link>), Simon Fougner Hartmanns Familiefond to N.G., the
Lundbeck foundation (R215-2015-4174) to A.A., the Novo Nordisk Foundation
(NNF15OC0017918 to N.G.; NNF16OC0019986 to N.G.; NNFCC0018486 to T.H.) and the
European Research Council (ERC) under the European Union's Horizon 2020
research and innovation programme (grant agreement no. 638173) to R.A.. The
Greenlandic health surveys (IHIT and B99) were supported by Karen Elise
Jensenâs Foundation, the Department of Health in Greenland, NunaFonden,
Medical Research Council of Denmark, Medical Research Council of Greenland, and the
Commission for Scientific Research in Greenland.</p>
    </ack>
    <fn-group>
      <fn id="FN1">
        <p id="P23">
<bold>URLs</bold>
</p>
        <p id="P24">Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal:
<ext-link ext-link-type="uri" xlink:href="http://www.type2diabetesgenetics.org/">http://www.type2diabetesgenetics.org/</ext-link></p>
        <p id="P25">Genome Aggregation Database (gnomAD): <ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">http://gnomad.broadinstitute.org/</ext-link></p>
        <p id="P26">GTEx Portal: <ext-link ext-link-type="uri" xlink:href="https://www.gtexportal.org/home/">https://www.gtexportal.org/</ext-link></p>
        <p id="P27">FastQC: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></p>
      </fn>
      <fn id="FN2" fn-type="con">
        <p id="P28">
<bold>Contributions</bold>
</p>
        <p id="P29">T.H. and A.A. conceived and headed the project. I.M. and A.A. designed
the statistical setup for the association testing, while T.H., N.G, M.K.A. and
O.P. designed the experimental setup for the DNA extraction, genotyping and
sequencing. M.E.J. and P.B. were PIs of the population studies in Greenland, and
together with C.V.L.L., and I.K.D.-P. they provided the Greenlandic samples,
collected and defined the phenotypes and provided context of these samples.
I.M., N.G., E.J. and A.A. performed the association analyses. T.K. and Y.M.
designed the experimental setup for RNA extraction and sequencing. A.G, D.S,
G.D. and E.Z. performed the loss-of-function analysis in the Greek cohorts.
K.V.S., M.D. and R.A. performed the RNA sequence analysis. N.G., I.M., M.K.A.,
A.A. and T.H. wrote the majority of the manuscript with input from all authors.
All authors approved the final version of the manuscript.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN3">
        <p id="P30">
<bold>Competing Financial Interests Statement</bold>
</p>
        <p id="P31">The authors report no competing financial interests.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moltke</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nature</source>
          <year>2014</year>
          <volume>512</volume>
          <fpage>190</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">25043022</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pedersen</surname>
              <given-names>CT</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Genetics</source>
          <year>2017</year>
          <volume>205</volume>
          <fpage>787</fpage>
          <lpage>801</lpage>
          <pub-id pub-id-type="pmid">27903613</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speliotes</surname>
              <given-names>EK</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>937</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">20935630</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warrington</surname>
              <given-names>NM</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Int J Epidemiol</source>
          <year>2015</year>
          <volume>44</volume>
          <fpage>700</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">25953783</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lek</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nature</source>
          <year>2016</year>
          <volume>536</volume>
          <fpage>285</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">27535533</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchsberger</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nature</source>
          <year>2016</year>
          <volume>536</volume>
          <fpage>41</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">27398621</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>The Sigma Type Diabetes Consortium</collab>
            <etal/>
          </person-group>
          <source>JAMA</source>
          <year>2014</year>
          <volume>311</volume>
          <fpage>2305</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">24915262</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohmueller</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Am J Hum Genet</source>
          <year>2013</year>
          <volume>93</volume>
          <fpage>1072</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">24290377</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laakso</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>J Lipid Res</source>
          <year>2017</year>
          <volume>58</volume>
          <fpage>481</fpage>
          <lpage>493</lpage>
          <pub-id pub-id-type="pmid">28119442</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panoutsopoulou</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nat Commun</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>5345</fpage>
          <pub-id pub-id-type="pmid">25373335</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e66883</fpage>
          <pub-id pub-id-type="pmid">23826166</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vitting-Seerup</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sandelin</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Mol Cancer Res</source>
          <year>2017</year>
          <volume>15</volume>
          <fpage>1206</fpage>
          <lpage>1220</lpage>
          <pub-id pub-id-type="pmid">28584021</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <source>Cell Signal</source>
          <year>2013</year>
          <volume>25</volume>
          <fpage>2413</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">23917208</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <source>J Mol Endocrinol</source>
          <year>2016</year>
          <volume>57</volume>
          <fpage>R93</fpage>
          <lpage>R108</lpage>
          <pub-id pub-id-type="pmid">27194812</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tong</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Sci Rep</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>34179</fpage>
          <pub-id pub-id-type="pmid">27678003</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pitman</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e110226</fpage>
          <pub-id pub-id-type="pmid">25329148</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <source>PLoS One</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>e6979</fpage>
          <pub-id pub-id-type="pmid">19750222</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Biol Psychiatry</source>
          <year>2016</year>
          <volume>80</volume>
          <fpage>836</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="pmid">26868444</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaisse</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Reiter</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Berbari</surname>
              <given-names>NF</given-names>
            </name>
          </person-group>
          <source>Cold Spring Harb Perspect Biol</source>
          <year>2017</year>
          <volume>9</volume>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dupuis</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>105</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="pmid">20081858</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tachmazidou</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Am J Hum Genet</source>
          <year>2017</year>
          <volume>100</volume>
          <fpage>865</fpage>
          <lpage>884</lpage>
          <pub-id pub-id-type="pmid">28552196</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bjerregaard</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Int J Circumpolar Health</source>
          <year>2003</year>
          <volume>62</volume>
          <issue>Suppl 1</issue>
          <fpage>3</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">14527126</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <name>
              <surname>Bjerregaard</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.si-folkesundhed.dk/upload/inuit_health_in_transition_Greenland_methods_5_2nd_revision.pdf">http://www.si-folkesundhed.dk/upload/inuit_health_in_transition_Greenland_methods_5_2nd_revision.pdf</ext-link>
          </comment>
          <year>2011</year>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Philipsen</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>e0123062</fpage>
          <pub-id pub-id-type="pmid">25849815</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>JÃ¸rgensen</surname>
              <given-names>ME</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Diabetes Care</source>
          <year>2013</year>
          <volume>36</volume>
          <fpage>2988</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">23656981</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthews</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Diabetologia</source>
          <year>1985</year>
          <volume>28</volume>
          <fpage>412</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">3899825</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutt</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Diabetes Res Clin Pract</source>
          <year>2000</year>
          <volume>47</volume>
          <fpage>177</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">10741566</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="book">
          <collab>World Health Organization Study Group</collab>
          <publisher-name>World Health Organization</publisher-name>
          <publisher-loc>Geneva</publisher-loc>
          <year>1999</year>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <source>PLoS Genet</source>
          <year>2016</year>
          <volume>12</volume>
          <fpage>e1006119</fpage>
          <pub-id pub-id-type="pmid">27341449</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Nat Genet</source>
          <year>2012</year>
          <volume>44</volume>
          <fpage>821</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">22706312</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Novembre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <source>Genome Res</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>1655</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">19648217</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moltke</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Albrechtsen</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Bioinformatics</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>1027</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="pmid">24215025</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bolger</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lohse</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Usadel</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Bioinformatics</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>2114</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">24695404</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Langmead</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Salzberg</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <source>Nat Methods</source>
          <year>2015</year>
          <volume>12</volume>
          <fpage>357</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">25751142</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrow</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Genome Res</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>1760</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">22955987</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Bioinformatics</source>
          <year>2015</year>
          <volume>31</volume>
          <fpage>2400</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">25617416</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>JT</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nat Biotechnol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>24</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">21221095</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>Bioinformatics</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>923</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">24227677</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trapnell</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nat Biotechnol</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>511</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">20436464</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Duggal</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Love</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Irizarry</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kingsford</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>Nat Methods</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>417</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">28263959</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Punta</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Nucleic Acids Res</source>
          <year>2012</year>
          <volume>40</volume>
          <fpage>D290</fpage>
          <lpage>301</lpage>
          <pub-id pub-id-type="pmid">22127870</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title><italic>ADCY3</italic> isoforms, observed loss-of-function variants and
functional consequences based on RNA sequencing of leukocytes from 17
Greenlandic individuals.</title>
        <p><bold>a.</bold> Schematic representation of <italic>ADCY3</italic> displaying the
three relevant transcript isoforms and their predicted functional consequences
annotated to the left (âCodingâ or ânonsense mediated decay
(NMD) sensitiveâ). The exons that correspond to the protein domain,
Guanylate cyclase, are shown as gray filled boxes, while the rest of the exons
are shown as black filled boxes. The red square encapsulates the exons affected
by the Greenlandic <italic>ADCY3</italic> c.2433-1G&gt;A variant. The
locations of the identified loss-of-function variants in <italic>ADCY3</italic>
in the Greenlandic and trans-ancestry cohorts are shown with arrows in red and
black, respectively. Variants were annotated to canonical transcript ADCY3-201
(NM_004036) except c.1072-1G&gt;A, which is annotated to alternative transcript
ADCY3-202 (NM_001320613). <bold>b.</bold>
<italic>ADCY3</italic> Transcripts Per Million (TPM) normalized gene expression,
stratified according to <italic>ADCY3</italic> c.2433-1G&gt;A variant
genotype groups (WT, wild type; HE, heterozygous; and HO, homozygous).
<bold>c.</bold>
<italic>ADCY3</italic> transcript isoform fractions for the three quantified
isoforms, the canonical isoform, the novel exon skipping and intron retention
splice version stratified according to <italic>ADCY3</italic> c.2433-1G&gt;A
variant genotype groups. Number of individuals in each group in b and c are: WT:
7 GG carriers, HE: 6 GA carriers, and HO: 4 AA carriers. The lower and upper
hinges of boxes in b and c correspond to the first and third quartiles of data,
respectively, while the middle line is the median and the whiskers extends to
the largest and smallest data points no further away than 1.5 times the
interquartile range.</p>
      </caption>
      <graphic xlink:href="emss-75137-f001"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="portrait">
      <label>Table 1</label>
      <caption>
        <title>Association of <italic>ADCY3</italic> c.2433-1G&gt;A with obesity and
type 2 diabetes-related traits in Greenlandic cohorts.</title>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="center" rowspan="1" colspan="1"/>
            <th align="center" rowspan="1" colspan="1"/>
            <th align="center" colspan="4" rowspan="1">Recessive model</th>
            <th align="center" colspan="4" rowspan="1">Additive model</th>
          </tr>
          <tr>
            <th align="left" rowspan="1" colspan="1">Trait</th>
            <th align="center" rowspan="1" colspan="1">
<italic>N</italic>
</th>
            <th align="center" rowspan="1" colspan="1">
<italic>Î²</italic>
<sub>SD</sub>
</th>
            <th align="center" rowspan="1" colspan="1">se<sub>SD</sub></th>
            <th align="center" rowspan="1" colspan="1">
<italic>Î²</italic>
</th>
            <th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th>
            <th align="center" rowspan="1" colspan="1">
<italic>Î²</italic>
<sub>SD</sub>
</th>
            <th align="center" rowspan="1" colspan="1">se<sub>SD</sub></th>
            <th align="center" rowspan="1" colspan="1">
<italic>Î²</italic>
</th>
            <th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Type 2 diabetes (cases/ controls)</td>
            <td align="left" rowspan="1" colspan="1">301/2,585</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">0.50</td>
            <td align="left" rowspan="1" colspan="1">
<bold>7.8Ã10<sup>-5</sup></bold>
</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">0.081</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.0014</bold>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
            <td align="left" rowspan="1" colspan="1">4,001</td>
            <td align="left" rowspan="1" colspan="1">1.2</td>
            <td align="left" rowspan="1" colspan="1">0.36</td>
            <td align="left" rowspan="1" colspan="1">7.3</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.00094</bold>
</td>
            <td align="left" rowspan="1" colspan="1">0.18</td>
            <td align="left" rowspan="1" colspan="1">0.075</td>
            <td align="left" rowspan="1" colspan="1">1.00</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.017</bold>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Fat percentage (%)</td>
            <td align="left" rowspan="1" colspan="1">2,701</td>
            <td align="left" rowspan="1" colspan="1">1.1</td>
            <td align="left" rowspan="1" colspan="1">0.35</td>
            <td align="left" rowspan="1" colspan="1">8.1</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.0024</bold>
</td>
            <td align="left" rowspan="1" colspan="1">0.18</td>
            <td align="left" rowspan="1" colspan="1">0.078</td>
            <td align="left" rowspan="1" colspan="1">1.56</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.024</bold>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/L)</td>
            <td align="left" rowspan="1" colspan="1">3,622</td>
            <td align="left" rowspan="1" colspan="1">0.77</td>
            <td align="left" rowspan="1" colspan="1">0.34</td>
            <td align="left" rowspan="1" colspan="1">0.76</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.022</bold>
</td>
            <td align="left" rowspan="1" colspan="1">0.12</td>
            <td align="left" rowspan="1" colspan="1">0.072</td>
            <td align="left" rowspan="1" colspan="1">0.11</td>
            <td align="left" rowspan="1" colspan="1">0.088</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">2-h plasma glucose (mmol/L)</td>
            <td align="left" rowspan="1" colspan="1">3,387</td>
            <td align="left" rowspan="1" colspan="1">0.73</td>
            <td align="left" rowspan="1" colspan="1">0.35</td>
            <td align="left" rowspan="1" colspan="1">2.3</td>
            <td align="left" rowspan="1" colspan="1">
<bold>0.035</bold>
</td>
            <td align="left" rowspan="1" colspan="1">0.13</td>
            <td align="left" rowspan="1" colspan="1">0.073</td>
            <td align="left" rowspan="1" colspan="1">0.45</td>
            <td align="left" rowspan="1" colspan="1">0.090</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <p id="P32">Results are shown for a recessive and an additive genetic model.
<italic>Î²</italic><sub>SD</sub> and SESD are the effect size and
standard error estimated using quantile transformed values of the trait
(except for the binary trait type 2 diabetes) and <italic>Î²</italic>
is the effect size estimated using untransformed values. The
<italic>P</italic>-values were obtained from the analyses of quantile
transformed traits (except for the binary trait type 2 diabetes).
<italic>P</italic>-values shown have not been corrected for multiple
testing and nominally significant <italic>P</italic>-values are highlighted
in bold.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>